BioSpace News Archive

The allowed patent includes 19 claims, key claims relating to the processing of multiple unique test devices simultaneously in a common drawer, mechanisms for decoding identifiers, and lateral flow test results based on line intensity/color.

The emerging landscape of tyrosine kinase inhibitors have shown to significantly enhance the survival rates in cancer patients owing to their ability to specifically target the genomic alterations which are critical for the progression of cancer.

InGeneron, Inc., a clinical stage biotechnology company, announced that the American Medical Association’s Current Procedural Terminology Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell therapy for partial thickness rotator cuff tears.

TransCode Therapeutics, Inc. announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference.

ResMed announced it plans to release financial and operational results for the second quarter of fiscal year 2022 on Thursday, January 27, 2022, after the New York Stock Exchange closes.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company’s Board of Directors.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to one new employee with a grant date of January 3, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Star Seyedkazemi, Pharm.D., joined Adverum as the company’s chief development officer.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has completed enrollment into its pivotal trial for the use of the RECELL® System for soft-tissue reconstruction.

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the addition of new employees to fill open roles in technical operations.